Investor Login
|
Home
|
Contact Us
Healthcare Venture Capital
About
Team
Portfolio
Media
Investors
Contact
Portfolio Companies
Accumetrics
Alereon
Apollo Endosurgery
Asuragen
BioForm
BioMimetic
BioSET
Cameron Health
Cardiva Medical
GlycoMimetics
IDEV Technologies
InSite Vision
Intersect ENT
LDR Spine
Mirna Therapeutics
On-X Life Technologies
Ortho Kinematics
OsteoBiologics
Tryton Medical
ZIOPHARM Oncology
News and Press
Dean Clay Johnston to Serve as Keynote Speaker at Annual Investors Meeting
PTV Announces Name Change, Expanded Capabilities, and Move to new Headquarters
PTV Recognized Among Top Consistent Performing Venture Capital Fund Managers
Accumetrics Obtains CE Mark for Therapeutic Window Claim on the VerifyNow P2Y12 Test
CE Mark for VerifyNow II System Caps a Strong 2012 for Accumetrics
8500+ Patient Trial Validates Association between High Platelet Reactivity and 1-Year Cardiovascular Outcomes at TCT 2012
Accumetrics Aligned with Medicare’s Hospital Readmissions Reduction Program
Accumetrics’ VerifyNow System Receives Health Canada License for Clinical Use
New CE Marked Prognostic Claim for the VerifyNow P2Y12 Test
Accumetrics Signs National Distribution Agreement with Cardinal Health
2011 ACCF/AHA Guidelines Incorporate New Recommendations for Platelet Reactivity Testing
back to top
Alereon Introduces New Wireless HDMI Video Solutions
Ultrawideband: Down, But Far From Out
WiMedia and UWB: where to from here?
Alereon Receives FCC Modular Certification for Worldwide Wireless USB Half-MiniCard
back to top
Apollo Endosurgery to Present at 32nd Annual J.P Morgan Healthcare Conference
Apollo Endosurgery Completes Acquisition of Allergan, Inc.’s Obesity Intervention Division
Apollo Endosurgery Annouces Acquisition of Obesity Intervention Division from Allergan, Inc.
Weight-Loss Surgery Beats Obesity Better Than Diet, Exercise
Apollo Endosurgery’s OverStitch™ Endoscopic Suturing Platform Launches in Europe
Apollo Endosurgery Named to FierceMedicalDevices “FIERCE 15” List of Top Private Medical Device Companies of 2012
Apollo Names Former Covidien Chairman and CEO Richard Meelia to Board
FDA Clears Apollo Endosurgery’s SuMO™ Endoscopic Tissue Access and Resection System
Apollo Endosurgery Announces First Incisionless Full-thickness Resection of a Colonic Polyp
Apollo Endosurgery Taps Michael Doty for CFO
New Class of Instruments for Flexible Surgery from Apollo Endosurgery Used in Cancer Therapy
Apollo Endosurgery Demonstrates Clinical Functionality of the Newly Launched OverStitch™
back to top
Asuragen to present at upcoming Association for Molecular Pathology Annual Meeting on Genomic Medicine
Asuragen launches SuraSeq™ Next Generation Sequencing Panel in its CAP accredited CLIA Laboratory
Asuragen launches SuraSeq™ Next Generation Sequencing Services
Rolland Carlson, Ph.D. named CEO of Asuragen
Asuragen to present at upcoming Association for Molecular Pathology Annual Meeting on Genomic Medicine
Asuragen Grants Armored RNA® Technology License to BD
Asuragen awarded $6.8 million commercialization award from CPRIT
Asuragen announces launch of Inform
TM
Thyroid Panel
Asuragen Reports Results from a Multi-Center Study on Fragile X Gene
Asuragen Announces New Notices of Allowance from USPTO Related to the Diagnostic Applications of Cancer-Related miRNAs
back to top
(NASDAQ: BFRM) - Acquired by: Merz
Merz to Acquire BioForm Medical
back to top
(NASDAQ: BMTI)
BioMimetic Therapeutics, Inc. Initiates Enrollment in Augment™ Chronic Tendinopathy Clinical Trial
Wright Medical Group, Inc. and BioMimetic Therapeutics, Inc. Enter Into Agreement to Combine Businesses
BioMimetic Therapeutics' Augment™ Bone Graft Receives Positive Recommendation from FDA Advisory Committee
BioMimetic Therapeutics, Inc. to Highlight Commercial and Product Development Activities during AAOS
BioMimetic Therapeutics Announces Date of FDA Advisory Panel Review of Augment(TM) Bone Graft
BioMimetic Therapeutics PMA Remains on Track
BioMimetic nears European patent on tissue healing products
Dr. Samuel E. Lynch Presides Over NASDAQ Closing Bell to Celebrate Initial Public Offering of BioMimetic Therapeutics, Inc. [BMTI]
back to top
Brookhaven Lab and BioSET, Inc., Patent a Synthetic Peptide That Enhances Bone Growth
BioSET Announces Initiation Of Clinical Trials For AMPLEX Osteo-Promotive Bone Graft System For Spine Fusion
Tornier and Bioset Enter Synthetic Growth Factor Pact
back to top
Boston Scientific Receives Prestigious 2013 Prix Galien Award For Innovative S-ICD® System
Boston Scientific Wins FDA Approval for Under-Skin Defibrillator
Cameron Health's S-ICD System Meets Primary Safety and Efficacy Endpoints in IDE Clinical Study
"A Life Saver" - Patient Article in the UK
Cameron Health's S-ICD System Scheduled for FDA Panel Review on April 26, 2012
Boston Scientific to Acquire Cameron Health, Inc.
Cameron Health Patient in the News - NCAA.com Aritcle
back to top
Cardiva Medical, Inc. Announces Appointment of Randy Hubbell, Chief Commercial Officer
Cardiva Medical, Inc. Announces U.S. FDA Approval for VASCADE™ Vascular Closure System
Cardiva Medical, Inc. announces that it has obtained approval to apply the European CE Mark to its VASCADE™ Closure System
Cardiva Medical, Inc. submits final PMA module to FDA for VASCADE™ Vascular Closure
Cardiva Medical, Inc. Announces Completion of Enrollment in the RESPECT Clinical Trial
Cardiva Medical, Inc. Announces U.S. Distribution for Hemostasis Products
Cardiva Medical, Inc. Announces Appointment of Charles Maroney, President and Chief Executive Officer
Cardiva Medical, Inc. Receives FDA Clearance for the Catalyst III System
back to top
GlycoMimetics Announces Closing of Initial Public Offering & Full Exercise of Underwriters' Option to Purchase Additional Shares
GlycoMimetics Announces Pricing of Initial Public Offering
Tech Council of Maryland Names Glycomimetics CEO Rachel King as 2013 Executive of the Year
Glycomimetics Completes Enrollment in Phase 2 Sickle Cell Disease Study with Lead Drug Candidate GMI-1070
GlycoMimetics Presented Progress from its Novel Compounds at 2012 American Society of Hematology Annual Meeting
GlycoMimetics Announces Two Key Leadership Promotions
GlycoMimetics, Inc. Attracts $38 Million in Latest Venture Round
New Drug to Treat Sickle Cell Crisis Begins Pilot Study in Patient
s
GlycoMimetics, Inc. Awarded NIH Grant to Study Drug Candidate in Diabetes
back to top
Abbott Completes Acquisition of IDEV Technologies
Abbott to Acquire IDEV Technologies to Expand Global Peripheral Technology Portfolio
Twelve-Month Outcomes of Popliteal Artery Treatment with Supera® System Published in JACC Cardiovascular Interventions
Results from RESTORE Study Demonstrate Positive Clinical Outcomes in Significantly Diseased Patients with Long Lesions
Clinical Results for the Supera® Peripheral Stent System Highlighted At Leading Global Peripheral Intervention Course
New Tactics To Treat Artery Disease That Harms Legs
IDEV Announces Positive Two-Year Clinical Outcomes from Long Term Registry of the SUPERA® Stent
IDEV's Pivotal SUPERB Trial Demonstrates SUPERA® Stent Significantly Exceeds VIVA Criteria for One-Year Patency
IDEV seeks to secure PMA for Supera stent
IDEV Technologies Introduces SUREPATH™ Guidewires
IDEV Technologies Strengthens Commercial Leadership
back to top
(INSV.OB)
InSite Vision Initiates Confirmatory Phase 3 Study of BromSite™ for Reduction of Inflammation and Pain after Cataract Surgery
InSite Vision Completes Phase 3 Clinical Study of BromSite for the Reduction of Pain and Inflammation After Cataract Surgery
InSite Vision Fully Enrolls Phase 3 Clinical Study of BromSite™ for the Reduction of Pain and Inflammation after Cataract Surgery
InSite Vision Introduces DuraSite 2® Ophthalmic Drug Delivery System
InSite Vision Initiates First Phase 3 Clinical Study of BromSite™ for the Reduction of Pain and Inflammation after Cataract Surgery
InSite Vision Receives Broad Patent Approval in Japan
InSite Vision Receives Special Protocol Assessment from FDA for DOUBle Phase 3 Clinical Trial of AzaSite Plus & DexaSite
back to top
Intersect ENT Named One of Forbes Magazine’s “America’s Most Promising Companies" of 2014
Forbes "America's Most Promising Companies" List
Intersect ENT to Present at the 32nd Annual JP Morgan Healthcare Conference
Intersect ENT Joins the FierceMedicalDevices' 2013 Fierce 15 List
Intersect ENT Announces Positive Results from Pilot Study of Novel In-Office Implant for Chronic Sinusitis Patients
Intersect ENT President and CEO Lisa Earnhardt Named One of Bay Area’s “Most Influential Women in Business”
Intersect ENT Vice President Susan Stimson Honored As “Marketer That Matters”
Intersect ENT Initiates U.S. Clinical Study of a Novel In-Office Treatment for Chronic Sinusitis Patients
Intersect ENT Announces FDA Approval of New Steroid-Releasing Implant
PROPEL Wins Internationally-Renowned Edison Award
Groundbreaking Clinical Evidence Demonstrates Benefit of PROPEL Implant for Chronic Sinusitis Patients
Intersect ENT Quadruples Operation Size with Expansion to New Facility in Menlo Park, Calif.
Intersect ENT Announces Positive Data from Pivotal Study of Propel Implant
Intersect ENT Announces U.S. FDA Approval for First Drug Releasing Implant for Chronic Sinusitis Patients
back to top
LDR Holding Corporation Reports Third Quarter 2013 Results
LDR Receives First FDA Approval for Two-Level Cervical Disc Replacement
LDR Files Registration Statement for Proposed Initial Public Offering
LDR Receives FDA Approval for the Mobi-C® Cervical Disc for One-Level Use
LDR Receives Approvable Letter from U.S. Food and Drug Administration for Two-Level Mobi-C® Cervical Disc
LDR Announces FDA Clearance of the Avenue® L Lateral Lumbar Cage System
LDR Announces FDA Clearance and Launch of the ROI-C® Lordotic Cervical Cage
LDR Holding Appoints Robert E. McNamara Chief Financial Officer
LDR Opens New and Expanded Global Headquarters in Austin, Texas
LDR receives approval to market two new stand-alone spine products in China
LDR Founder, President and CEO Named a 2011 Ernst & Young Entrepreneur Of The Year
®
for the Central Texas Region
back to top
Mirna Therapeutics Reports Expansion of Intellectual Property Estate
Marina Biotech and Mirna Therapeutics Amend License Agreement for the Development of microRNA-based Therapeutics
Mirna Therapeutics Expands Oncology Scientific Advisory Council
Mirna Therapeutics Announces Important Expansion of microRNA Patent Portfolio
Mirna Therapeutics Appoints Dr. Sinil Kim as Chief Medical Officer
Mirna Therapeutics is First to Advance MicroRNA into the Clinic for Cancer
Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of Directors
Mirna Therapeutics Publishes Preclinical Data Demonstrating Therapeutic Effects of microRNA in Hematological Cancer
Marina Biotech and Mirna Therapeutics Announce License
Mirna Therapeutics to Moderate Session on Promise of miRNAs in Cancer at BIO International Convention
Mirna Therapeutics and Collaborators Publish New Data on miR-34 and its Role in Cancer Stem Cells
Mirna Therapeutics reports notice of allowance from USPTO related to clinical application of an important cancer-related miRNA
back to top
On-X Life Technologies reports CE mark approval to sell mechanical aortic heart valve with expanded labeling claim
On-X Heart Valve Study Results Presented at the Society for Heart Valve Disease 7th Biennial Congress
Economic Model of the Life-time Cost Impact of Heart Valve Prosthetic Choice to be Presented at ISPOR Meeting
Enrollment Completed for Low-Risk Aortic and Mitral Patient Groups for On-X Prosthetic Heart Valve Anticoagulation Clinical Study
AATS Report: Prospective Randomized On-X Heart Valve Clinical Trial (PROACT) Provides Evidence of Reduced Complications
Predicting Long-Term Costs of Heart Valve Replacement Study to be Presented at American College of Cardiology Meeting
On-X LTI Receives FDA Approval for On-X Heart Valve with Anatomic Shaped Sewing Ring
On-X LTI Launches CHORD-X™ ePTFE Suture for Mitral Valve Repair and Replacement at STS 2013
On-X Life Technologies Submits for FDA/CE Approval of Reduced Anticoagulation Indication for On-X Aortic Heart Valve
On-X LTI Launches Innovative Heart Valve Products at European Meeting in Barcelona
The On-X® Heart Valve Compares Favorably to Tissue Valves
Austin Company Keeps GI's Heart Beating
back to top
Ortho Kinematics Receives FDA 510(k) Clearance to expand into Cervical Spine
Ortho Kinematics' back diagnostic device lands expanded clearance
KineGraph Study: Finding the Right Patient
Gov. Perry: We Must Invest Wisely to Help Texans and Strengthen Our Economy
back to top
Smith & Nephew Acquires OBI, Inc.
back to top
Tryton Medical Receives CE-mark for the Left Main Indication
Tryton Medical Establishes Bifurcation Institute
Tryton Medical Announces First Results From Pivotal Study of the Tryton Side Branch Stent
Tryton Medical Introduces Physician Education Program
Tryton Medical Announces Successful Live Case Transmission With New Tryton Side Branch SHORT Stent
Tryton Medical Announces Nordic-Baltic Dedicated Bifurcation Trial
Tryton Medical Announces CE Mark and European Launch of Next-Generation Tryton Side Branch SHORT Stent
Tryton Medical Announces Events at EuroPCR 2013 in Paris
Tryton Medical Announces Completion of Patient Enrollment in Landmark Pivotal Study
Tryton Announces Postive Clinical Data from More Than 900 Patients
4000th Patient Treated With Innovative Tryton Side Branch Stent
Tryton Announces Positive Data from Three European Registries
back to top
(NASDAQ: ZIOP)
ZIOPHARM Reports Positive Preliminary Palifosfamide Overall Survival Data from Randomized Phase 2 Study
ZIOPHARM Oncology Announces First Patient Dosed in Phase I Study of ZIN ATI-001 in Advanced Melanoma
ZIOPHARM Oncology Appoints Hagop Youssoufian, M.Sc., M.D., as Executive Vice President and Chief Medical Officer
ZIOPHARM and Solasia Pharma Announce License and Collaboration Agreement for Darinaparsin in Asia
ZIOPHARM Oncology Announces First Patient Dosed in Phase I Study of Palifosfamide in Small Cell Lung and Other Cancers
ZIOPHARM Presents Positive Darinaparsin Clinical Data at ASCO's Prestigious Clinical Science Symposium
back to top
For Media Assistance, please contact
Alexa Bourdage
at 512.872.4011.
Home
|
Site Map
|
Contact Us
All rights reserved 2014 PTV Healthcare Capital